COMMUNICATIONS
(for detailed procedure, see the Supporting Informa-
tion); b) G. L. Card, B. P. England, Y. Suzuki, D. Fong,
B. Powell, B. Lee, C. Luu, M. Tabrizizad, S. Gillette,
P. N. Ibrahim, D. R. Artis, G. Bollag, M. V. Milburn,
S. H. Kim, J. Schlessinger, K. Y. Zhang, Structure 2004,
12, 2233.
Experimental Section
Typical Procedure for Preparation of Compound 3a
A
mixture of 4-chloro-N-(4-chloro-2-iodophenyl)-2-nitro-
benzamide (1a) (0.24 mmol), K2CO3 (0.74 mmol), methyl 2-
cyanoacetate (2b) (0.29 mmol) and CuI (0.024 mmol) in
DMSO (2 mL) was heated at 858C under the open air for
2 h. After completion of the reaction, the mixture was
cooled to room temperature, diluted with ethyl acetate
(15 mL) and passed through celite. The filtrate was collect-
ed, washed with water (3ꢃ15 mL) followed by brine solu-
tion (25 mL), dried over anhydrous Na2SO4, filtered and
concentrated under reduced pressure. The residue was puri-
fied by column chromatography using ethyl acetate-hexane
to give the desired product 3a.
[6] a) R. A. Bunce, J. E. Schammerhorn, J. Heterocycl.
Chem. 2006, 43, 1031; b) J. Irurre, F. Marquillas, A. Al-
varez-Larena, J. F. Piniella, Can. J. Chem. 1994, 72, 33;
c) A. K. Sinha, S. Nizamuddin, Indian J. Chem. Sec B:
1984, 23, 165; d) A. Fecher, H. Fretz, K. Hilpert, M.
Riederer, World Patent Application No WO2005/94816
A1, 2005.
[7] For selected Cu-mediated domino reaction, see: a) M.
Jiang, J. Li, F. Wang, Y. Zhao, X. Dong, W. Zhao, Org.
Lett. 2012, 14, 1420; b) T. Liu, C. Zhu, H. Yang, H. Fu,
Adv. Synth. Catal. 2012, 354, 1579; c) J. Lu, X. Gong,
H. Yang, H. Fu, Chem. Commun. 2010, 46, 4172;
d) V. A. Vaillard, R. A. Rosi, S. E. Martin, Org.
Biomol. Chem. 2011, 9, 4927; e) B. Zou, Q. Yuan, D.
Ma, Angew. Chem. 2007, 119, 2652; Angew. Chem. Int.
Ed. 2007, 46, 2598.
[8] <For very recent and selected examples on the use of
the nitro group in organic synthesis, see: a) K. Bera,
N. S. Satam, I. N. N. Namboothiri, J. Org. Chem. 2016,
81, 5670; b) T. Kumar, N. S. Satam, I. N. N. Namboo-
thiri, Eur. J. Org. Chem. 2016, 3316; c) P. Basu, P. Pra-
kash, E. Gravel, N. Shah, K. Bera, E. Doris, I. N. N.
Namboothiri, ChemCatChem 2016, 8, 1298; d) V.
Mane, J. Pandey, N. Ayyagari, C. Dey, R. Kale, I. N. N.
Namboothiri, Org. Biomol. Chem. 2016, 14, 2427.
[9] For a Cu-mediated displacement of the NO2 group by
a thiol reactant, see: S. S. Bahekar, A. P. Sarkate, V. M.
Wadhai, P. S. Wakte, D. B. Shinde, Catal. Commun.
2013, 41, 123.
Acknowledgements
RS thank CSIR, for a research fellowship. The authors thank
DBT, India (Grant BT/PR4286/BRB/10/1012/2011) for sup-
port.
References
[1] a) For HIV-1 reverse transcriptase inhibitory properties
of dipyridodiazepinones, pyridobenzoxazepinones and
dibenzoxazepinones, see: J. M. Klunder, K. D. Har-
grave, M. West, E. Cullen, K. Pal, M. L. Behnke, S. R.
Kapadia, D. W. McNeil, J. C. Wu, G. C. Chow, J.
Adams, J. Med. Chem. 1992, 35, 1887; b) for antiar-
rhythmic defibrillatory activity of dibenzo[b,e][1,4]di-
ACHTUNGTRENNUNGazepin-11-one and dibenzo[b,e][1,4]diazepine deriva-
[10] P. Wang, J. G. Myers, P. Wu, B. Cheewatrakoolpong,
R. W. Egan, M. M. Billah, Biochem. Biophys. Res.
Commun. 1997, 234, 320.
[11] a) B. Siegmund, J. Welsch, F. Loher, Leukemia 2001,
15, 1564. b) In addition to inducing apoptosis, inhibition
of PDE4 has also been reported to induce growth sup-
tives, see: O. Levy, M. Erez, D. Varon, E. Keinan,
Bioorg. Med. Chem. Lett. 2001, 11, 2921.
[2] a) M. Bigioni, A. Ettorre, P. Felicetti, S. Mauro, C.
Rossi, C. A. Maggi, E. Marastoni, M. Binaschi, M. Par-
lani, D. Fattori, Bioorg. Med. Chem. Lett. 2012, 22,
5360; b) W. Newman, C. F. Schwender, C. R. Mackay,
J. C. Pinto, World Patent Application No. WO1999/
37617 A1, 1999; c) J. R. Luly, Y. Nakasato, E. Ohshima
H. Sone, O. Kotera, G. C. B. Harriman, K. G. Carson,
World Patent Application No. WO2001/9094 A2, 2001;
d) A. Dhainaut, G. Regnier, G. Atassi, A. Pierre, S.
Leonce, L. Kraus-Berthier, J. F. Prost, J. Med. Chem.
1992, 35, 2481.
[3] H. P. Ng, M. Karen, J. G. Bauman, A. Ghannam, I.
Islam, M. Liang, R. Horuk, J. Hesselgesser, R. M.
Snider, H. D. Perez, M. M. Morrissey, J. Med. Chem.
1999, 42, 4680.
[4] a) S. B. Christensen, P. E. Bender, C. J. Forster, U.S.
Patent Application US 5,811,455, 1998; b) for s similar
class of compounds, see: A. Kodimuthali, S. S. L. Jaba-
ris, M. Pal, J. Med. Chem. 2008, 51, 5471.
pression,
glucocorticoid
sensitivity,
p53,
and
p21(WAF1/CIP1) proteins in human acute lymphoblas-
tic leukemia cells; see: R. Ogawa, M. B. Streiff, A. Bu-
gayenko, G. J. Kato, Blood 2002, 99, 3390.
[12] Pharmacological effects of small molecules in early de-
velopment can be assessed in embryos of zebrafish
Danio rerio that are considered as excellent animal
models for such a study. This allows effective in vivo
evaluations of potential drugs before embarking on ex-
pensive studies in mice and higher animals. a) M. West-
erfield, The Zebrafish Book. a Guide for the Laborato-
ry Use of Zebrafish (Danio rerio), 4th edn., University
of Oregon Press, Eugene, OR, 2000; b) A. Nakhi, S.
Archana, G. P. Seerapu, K. S. Chennubhotla, K. L.
Kumar, P. Kulkarni, D. Haldar, M. Pal, Chem.
Commun. 2013, 49, 6268; c) J. A. Ellard, U.S. Patent
Application No. US 4,080,325 A, 1978.
[5] a) The molecular docking simulations were carried out
using the GRIP method of docking in Biopredicta
module of Vlife MDS (Molecular Design Suite) 4.6.
Adv. Synth. Catal. 0000, 000, 0 – 0
5
ꢁ 2016 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
ÞÞ
These are not the final page numbers!